Latest News in the pharma Industry

Research & Development

AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

6 Aug 2017

FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .

Read more 
IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity

IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity

3 Aug 2017

The launch represents a major step towards therapeutic use of CRISPR.

Read more 
BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

3 Aug 2017

Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read more 
Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis

Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis

31 Jul 2017

Results from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.

Read more 
BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo and Rubraca

BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo and Rubraca

31 Jul 2017

Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.

Read more 
Arch Biopartners' GMP manufacturing of AB569 on schedule

Arch Biopartners' GMP manufacturing of AB569 on schedule

30 Jul 2017

Dalton Pharma Services is preparing glass vials in three varying dose formulations for the clinical kits needed to support the Phase I safety trial for AB569 at the CVAMC later this year.

Read more 
Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and US-formulated Humira

Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and US-formulated Humira

30 Jul 2017

First study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate.

Read more 
AstraZeneca and Merck establish oncology collaboration

AstraZeneca and Merck establish oncology collaboration

30 Jul 2017

Collaboration aims to maximize the potential of PARP and MEK inhibitors in combination with PD-L1/PD-1 medicines, based on growing scientific evidence that these combinations offer new potential for the treatment of a range of tumor types.

Read more 
Bavarian Nordic and Janssen to develop vaccine regimens against HIV-1 and Hepatitis B

Bavarian Nordic and Janssen to develop vaccine regimens against HIV-1 and Hepatitis B

27 Jul 2017

Deal builds on ongoing collaboration to develop vaccines for Human Papillomavirus (HPV) and Ebola.

Read more 
BMS's Orencia receives second EC approval in less than a year

BMS's Orencia receives second EC approval in less than a year

26 Jul 2017

New approval for treatment of active psoriatic arthritis (PsA).

Read more 
Long-acting injection to remove daily dosing burden for HIV patients?

Long-acting injection to remove daily dosing burden for HIV patients?

24 Jul 2017

Study results showed that long-acting cabotegravir and rilpivirine maintained viral suppression.

Read more 
Lilly backs Nektar Therapeutics' novel immunological therapy

Lilly backs Nektar Therapeutics' novel immunological therapy

24 Jul 2017

NKTR-358 has the potential to treat a number of autoimmune and other chronic inflammatory conditions.

Read more